The article includes a discussion of the manufacturing challenges for a customized therapy (~22 days and need for tracking) by Novartis vs an off-the-shelf therapy by Cellectis, which was recently put into clinical trial.
https://www.theatlantic.com/health/archive/2017/08/fda-appro…